A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
Anagrelide AOP is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation. Pierre Fabre is the MA-Holder and AOP Orphan has the distribution right.
Canemes® contains the active ingredient nabilone, a synthetically produced substance belonging to a group of compounds called cannabinoids (derived from cannabis plant). Canemes® prevents nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients